Patents by Inventor Valerie Ferreira

Valerie Ferreira has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MEANS AND METHODS FOR AAV GENE THERAPY IN HUMANS
    Publication number: 20220395545
    Abstract: The present invention relates to means and method for AAV based gene therapies in humans. In particular, the present invention relates to the treatment of human patients that may be suspected to have antibodies directed against the AAV intended for use in the treatment.
    Type: Application
    Filed: June 30, 2022
    Publication date: December 15, 2022
    Applicant: uniQure IP B.V.
    Inventors: Bart Antonius NIJMEIJER, Valerie FERREIRA
  • Means and methods for AAV gene therapy in humans
    Patent number: 11452749
    Abstract: The present invention relates to means and method for AAV based gene therapies in humans. In particular, the present invention relates to the treatment of human patients that may be suspected to have antibodies directed against the AAV intended for use in the treatment.
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: September 27, 2022
    Assignee: UNIQURE IP B.V.
    Inventors: Bart Antonius Nijmeijer, Valerie Ferreira
  • IMMUNOADSORPTION
    Publication number: 20210353776
    Abstract: Upon administration of rAAV vectors the humoral immune response (neutralizing antibodies) is the first barrier that needs to be overcome. Surprisingly it was found that by using immunoadsorption for depletion of immunoglobulins from the blood (plasma), subjects can be highly efficiently treated with rAAV vectors, i.e. obtain highly efficient transduction after rAAV vector administration, in spite of the presence of high levels of nAb.
    Type: Application
    Filed: June 3, 2021
    Publication date: November 18, 2021
    Applicant: uniQure IP B.V.
    Inventor: Valerie FERREIRA
  • Immunoadsorption
    Patent number: 11033639
    Abstract: Upon administration of rAAV vectors the humoral immune response (neutralizing antibodies) is the first barrier that needs to be overcome. Surprisingly it was found that by using immunoadsorption for depletion of immunoglobulins from the blood (plasma), subjects can be highly efficiently treated with rAAV vectors, i.e. obtain highly efficient transduction after rAAV vector administration, in spite of the presence of high levels of nAb.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: June 15, 2021
    Assignee: UNIQURE IP B.V.
    Inventor: Valerie Ferreira
  • METHODS OF IMPROVING ADENO-ASSOCIATED VIRAL TRANSDUCTION
    Publication number: 20200360535
    Abstract: Described herein are saturating agents, AAV gene therapy vectors, and therapeutic agents, as well as methods and kits comprising the same.
    Type: Application
    Filed: June 9, 2020
    Publication date: November 19, 2020
    Applicant: uniQure IP B.V.
    Inventor: Valerie FERREIRA
  • IMMUNOADSORPTION
    Publication number: 20190269800
    Abstract: Upon administration of rAAV vectors the humoral immune response (neutralizing antibodies) is the first barrier that needs to be overcome. Surprisingly it was found that by using immunoadsorption for depletion of immunoglobulins from the blood (plasma), subjects can be highly efficiently treated with rAAV vectors, i.e. obtain highly efficient transduction after rAAV vector administration, in spite of the presence of high levels of nAb.
    Type: Application
    Filed: April 15, 2019
    Publication date: September 5, 2019
    Applicant: uniQure IP B.V.
    Inventor: Valerie FERREIRA
  • Immunoadsorption
    Patent number: 10286087
    Abstract: Upon administration of rAAV vectors the humoral immune response (neutralizing antibodies) is the first barrier that needs to be overcome. Surprisingly it was found that by using immunoadsorption for depletion of immunoglobulins from the blood (plasma), subjects can be highly efficiently treated with rAAV vectors, i.e. obtain highly efficient transduction after rAAV vector administration, in spite of the presence of high levels of nAb.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: May 14, 2019
    Assignee: UNIQURE IP B.V.
    Inventor: Valerie Ferreira
  • MEANS AND METHODS FOR AAV GENE THERAPY IN HUMANS
    Publication number: 20190008909
    Abstract: The present invention relates to means and method for AAV based gene therapies in humans. In particular, the present invention relates to the treatment of human patients that may be suspected to have antibodies directed against the AAV intended for use in the treatment.
    Type: Application
    Filed: July 10, 2018
    Publication date: January 10, 2019
    Applicant: uniQure IP B.V.
    Inventors: Bart Antonius NIJMEIJER, Valerie FERREIRA
  • IMMUNOADSORPTION
    Publication number: 20180169273
    Abstract: Upon administration of rAAV vectors the humoral immune response (neutralizing antibodies) is the first barrier that needs to be overcome. Surprisingly it was found that by using immunoadsorption for depletion of immunoglobulins from the blood (plasma), subjects can be highly efficiently treated with rAAV vectors, i.e. obtain highly efficient transduction after rAAV vector administration, in spite of the presence of high levels of nAb.
    Type: Application
    Filed: December 15, 2017
    Publication date: June 21, 2018
    Applicant: uniQure IP B.V.
    Inventor: Valerie Ferreira